# Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer

Source: https://onco.cc/trials/nct07558733/  
OnCo record `nct07558733` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Serabelisib, Sapanisertib and Fulvestrant in advanced solid tumours, run by Faeth Therapeutics, now recruiting.

## Summary

Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer is a phase 1/2 interventional study registered as NCT07558733 by Faeth Therapeutics, with 32 participants planned, started 2026-04-22 and due to reach its primary completion in 2029-05. Interventions recorded: Serabelisib, Sapanisertib and Fulvestrant.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07558733
- Phase: 1/2
- Setting: Open-Label Umbrella Study to Evaluate Safety and Efficacy of Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced or Metastatic Breast Cancer
- Sponsor: Faeth Therapeutics
- Enrolled: 32

## Sources

- ClinicalTrials.gov NCT07558733: https://clinicaltrials.gov/study/NCT07558733

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Fulvestrant](https://onco.cc/drugs/fulvestrant/), [Sapanisertib](https://onco.cc/drugs/sapanisertib/), [Serabelisib](https://onco.cc/drugs/serabelisib/)

---
JSON: https://onco.cc/api/v1/entities/nct07558733.json